Welgene Biotech Co.,Ltd. (6661.TWO)

TWD 19.5

(1.04%)

Operating Expenses Summary of Welgene Biotech Co.,Ltd.

Welgene Biotech Co.,Ltd.'s latest annual operating expenses in 2023 was 123.97 Million TWD , down -1.07% from previous year.
Welgene Biotech Co.,Ltd.'s latest quarterly operating expenses in 2024 Q2 was 26.18 Million TWD , up 2.99% from previous quarter.
Welgene Biotech Co.,Ltd. reported a annual operating expenses of 125.92 Million TWD in annual operating expenses 2022, up 6.21% from previous year.
Welgene Biotech Co.,Ltd. reported a annual operating expenses of 118.56 Million TWD in annual operating expenses 2021, down -5.79% from previous year.
Welgene Biotech Co.,Ltd. reported a quarterly operating expenses of 31.56 Million TWD for 2024 Q1, up 0.36% from previous quarter.
Welgene Biotech Co.,Ltd. reported a quarterly operating expenses of 31.45 Million TWD for 2023 Q4, down -9.51% from previous quarter.

Annual Operating Expenses Chart of Welgene Biotech Co.,Ltd. (2023 - 2014)

Historical Annual Operating Expenses of Welgene Biotech Co.,Ltd. (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	123.97 Million TWD	-1.07%
2022	125.92 Million TWD	6.21%
2021	118.56 Million TWD	-5.79%
2020	125.84 Million TWD	-6.99%
2019	135.3 Million TWD	-2.79%
2018	139.19 Million TWD	19.06%
2017	116.9 Million TWD	2.88%
2016	113.63 Million TWD	-5.33%
2015	120.03 Million TWD	-12.93%
2014	137.85 Million TWD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	26.18 Million TWD	2.99%
2024 Q1	31.56 Million TWD	0.36%
2023 Q4	31.45 Million TWD	-9.51%
2023 FY	124.57 Million TWD	-1.07%
2023 Q1	26.64 Million TWD	-14.07%
2023 Q2	31.72 Million TWD	19.07%
2023 Q3	34.76 Million TWD	9.58%
2022 Q2	31.34 Million TWD	-10.46%
2022 Q4	31 Million TWD	8.47%
2022 Q3	28.57 Million TWD	-8.82%
2022 Q1	35 Million TWD	-6.61%
2022 FY	125.92 Million TWD	6.21%
2021 Q3	29.96 Million TWD	20.08%
2021 FY	118.56 Million TWD	-5.79%
2021 Q4	37.48 Million TWD	25.08%
2021 Q1	26.15 Million TWD	-27.72%
2021 Q2	24.95 Million TWD	-4.61%
2020 FY	125.84 Million TWD	-6.99%
2020 Q4	36.18 Million TWD	15.65%
2020 Q3	31.29 Million TWD	11.18%
2020 Q2	28.14 Million TWD	-6.86%
2020 Q1	30.21 Million TWD	-28.88%
2019 FY	135.3 Million TWD	-2.79%
2019 Q4	42.48 Million TWD	16.92%
2019 Q3	36.34 Million TWD	27.72%
2019 Q2	28.45 Million TWD	0.0%
2019 Q1	28.45 Million TWD	-22.03%
2018 Q2	33.79 Million TWD	0.0%
2018 FY	139.19 Million TWD	19.06%
2018 Q1	33.79 Million TWD	2.83%
2018 Q3	36.49 Million TWD	7.99%
2018 Q4	36.49 Million TWD	0.0%
2017 Q3	32.86 Million TWD	28.97%
2017 Q2	25.48 Million TWD	0.0%
2017 Q4	32.86 Million TWD	0.0%
2017 FY	116.9 Million TWD	2.88%
2017 Q1	25.48 Million TWD	-16.41%
2016 FY	113.63 Million TWD	-5.33%
2016 Q4	30.48 Million TWD	0.0%
2016 Q3	30.48 Million TWD	4.78%
2016 Q2	29.08 Million TWD	0.0%
2016 Q1	29.08 Million TWD	0.0%
2015 FY	120.03 Million TWD	-12.93%
2014 FY	137.85 Million TWD	0.0%

Peer Operating Expenses Comparison of Welgene Biotech Co.,Ltd.

Name	Operating Expenses	Operating Expenses Difference
BIONET Corp.	553.58 Million TWD	77.605%
DIVA Laboratories, Ltd.	158.62 Million TWD	21.842%
Genetics Generation Advancement Corp.	218.25 Million TWD	43.197%
Puriblood Medical Co., Ltd.	56.92 Million TWD	-117.783%
TFBS Bioscience Inc.	77.82 Million TWD	-59.292%